Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

15.80
+0.40002.60%
Pre-market: 16.100.3000+1.90%07:36 EDT
Volume:124.87K
Turnover:1.96M
Market Cap:214.88M
PE:-3.95
High:16.00
Open:15.39
Low:15.19
Close:15.40
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:0.55
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.68
PE(LYR):-2.53

Loading ...

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

TIPRANKS
·
May 29

Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

Reuters
·
May 28

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Cmsc Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 28

Immunic Appoints New CEO to Lead MS Strategy

TIPRANKS
·
May 27

Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt

Reuters
·
May 27

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

THOMSON REUTERS
·
May 27

Immunic Is Maintained at Buy by B. Riley Securities

Dow Jones
·
May 22

B. Riley cuts Immunic target, sees ‘compelling entry point’

TIPRANKS
·
May 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)

TIPRANKS
·
May 22

B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating

MT Newswires Live
·
May 22

Immunic director Michael W. Bonney files initial beneficial ownership statement

Reuters
·
May 20

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

Reuters
·
May 19

Immunic Inc - Simona Skerjanec Transitions From Interim Chairperson to Board Member

THOMSON REUTERS
·
May 19

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

THOMSON REUTERS
·
May 19

Immunic (IMUX) Gets a Buy from LifeSci Capital

TIPRANKS
·
May 18

Immunic price target lowered to $19 from $26 at Roth Capital

TIPRANKS
·
May 14